Alzheimer's Disease

Blood-Brain Barrier Bypassed, Diagnostic Potential Seen

Published in Gene Therapy Weekly, November 13th, 1995

Potential for premortem diagnostic test for Alzheimer's disease (AD) is possible with vector-mediated delivery of a labelled peptide through the blood-brain barrier (BBB).

Currently, Alzheimer's disease cannot be conclusively diagnosed until after the patient dies. A possible diagnostic approach would be to develop a premortem brain scan that could allow for semiquantitation of the A(beta) amyloid burden in human brain.

A study by J.E. Maggio et al., published in the 1992 Proceedings of the National Academy of Sciences (89:5462-66), using frozen postmortem sections of AD brain showed that ¹²⁵I-labeled A(beta)^1-40...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-11-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry